New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
43 minutes ago
0
0









